In a milestone for regenerative medicine, researchers at King’s College London have announced the first successful clinical trial of a stem cell therapy to repair damaged spinal cords. The trial, funded jointly by the Medical Research Council and the Wellcome Trust, involved 12 patients with complete thoracic spinal cord injuries. After a single injection of neural stem cells derived from induced pluripotent stem cells, six patients regained the ability to walk with assistance, and four recovered bladder function.
The results, published in The Lancet, represent a decisive shift from laboratory promise to clinical reality. Lead investigator Professor James Morrison described the outcome as “a turning point, not just for spinal cord injury but for the entire field.” The treatment works by creating a cellular bridge across the lesion site, allowing severed nerve fibres to reconnect.
Side effects were limited to mild immunosuppression, manageable with standard drugs. The next phase will extend the trial to cervical injuries, which affect arm and hand function. Downing Street has already pledged an additional £50 million for rapid expansion.
The breakthrough comes amid growing UK investment in stem cell research, positioning Britain at the forefront of neurological repair.
